Home › Research › Health systems and care delivery
Unlocking ocular biomarkers for early detection of Alzheimer's disease
Dave Nikhil, Lee Melissa, Pavlou Hania, Im Owen, Goh Kim, Ulin Sam, Malzbender Kristina, Shobin Eli et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025-02-19
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Recent evidence suggests that ocular testing holds promise as a non-invasive and cost-effective method for the early detection of Alzheimer's disease (AD). After interviews with neurologists, optometrists, primary care physicians, and ophthalmologists, the potential for ocular biomarker testing to become a standard clinical practice in the future was assessed. Ocular tests offer a non-invasive alternative to blood-based testing, capturing a substantial niche of ≈ 4 to 8 million individuals in the United States during routine eye exams. Technical requirements for broad adoption include high accuracy comparable to blood-based tests and 510(k) clearance. Ocular biomarker technology must meet the practical requirements of optometrists and ophthalmologists, including ease of implementation, automation, and a clear path to profitability. A sufficient body of evidence to support guideline inclusion, reimbursement, and clinical actionability will facilitate the adoption. As the field evolves, advances such as earlier detection of preclinical AD may further expand the role of ocular testing. HIGHLIGHTS: Ocular biomarkers offer another non-invasive alternative to blood-based Alzheimer's disease testing. Wide adoption will require accuracy akin to blood-based tests and 510(k) clearance. Ocular screening could benefit ≈ 4 to 8 million US individuals conducting routine eye exams. Current ocular offerings remain nascent, and advances could expand this reach. New technology must show ease of implementation, automation, and a path to profit.
What this study adds
Evidence grade: Low
This paper assesses the potential for ocular biomarker testing to become standard practice for early detection of Alzheimer's disease. It describes technical and practical requirements for adoption and does not test any treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Nikhil, D., Melissa, L., Hania, P., Owen, I., Kim, G., Sam, U., et al. (2025). Unlocking ocular biomarkers for early detection of Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.14567
Vancouver
Nikhil D, Melissa L, Hania P, Owen I, Kim G, Sam U, et al. Unlocking ocular biomarkers for early detection of Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. doi:10.1002/alz.14567. PMID: 39968707.
BibTeX
@article{nikhil2025-39968707,
author = {Nikhil, Dave and Melissa, Lee and Hania, Pavlou and Owen, Im and Kim, Goh and Sam, Ulin and Kristina, Malzbender and Eli, Shobin and others},
title = {{Unlocking ocular biomarkers for early detection of Alzheimer's disease}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2025},
doi = {10.1002/alz.14567},
pmid = {39968707},
url = {https://doi.org/10.1002/alz.14567}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Recent evidence suggests that ocular testing holds promise as a non-invasive and cost-effective method for the early detection of Alzheimer's disease (AD).
Why it matters
This paper assesses the potential for ocular biomarker testing to become standard practice for early detection of Alzheimer's disease. It describes technical and practical requirements for adoption and does not test any treatment, cure, or prevention.
Study details
- Evidence strengthLow
How this study scored 38/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 36 of the 96 points we could judge it on, which is 38 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-17) |
| Citations per year | 1 / 5 | 2.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 0 / 3 | Alzheimer's Drug Discovery Foundation: institution h-index 73 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39968707) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 36 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 36 of the 96 points we could judge it on is 38 out of 100. |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Health systems and care delivery from nearby years
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.